Hyperthyroidism due to familial pituitary resistance to thyroid hormone: successful control with 3, 5, 3′ triiodothyroacetic associated to propranolol

Diosdado, Manuel Aguilar; Escobar-Jimenez, Luis; Soto, María Luisa Fernández; Curiel, Arturo; Escobar-Jiménez, Fernándo

doi:10.1007/bf03347890

Cited by 14 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a subgroup of RTHβ patients, TA 3 is able to decrease TSH and consequently the high serum T 4 and T 3 levels. Since the thyromimetic effects of TA 3 itself do not fully compensate the reduction in endogenous TH levels, it alleviates the thyrotoxic symptoms including tachycardia, goiter, excessive sweating and behavioral problems (BeckPeccoz et al 1983, Lind & Eber 1986, Faglia et al 1987, Salmela et al 1988, Kunitake et al 1989, Smallridge et al 1989, Beck-Peccoz et al 1990, Aguilar Diosdado et al 1991 Crino et al 1992, Dulgeroff et al 1992, Ueda et al 1996, Darendeliler & Basx 1997, Radetti et al 1997, CliftonBligh et al 1998, Persani et al 1998, Asteria et al 1999, Kong et al 2005, Torre et al 2005, Wu et al 2006, Gurgel et al 2008, Santos et al 2008, Guran et al 2009, Anzai et al 2012, Ferrara et al 2012, Ramos-Prol et al 2013, Stagi et al 2014, Chatzitomaris et al 2015, Xue et al 2015. However, some patients do not respond to TA 3 treatment, which is assumed to depend on the type or location of the mutation (Hamon et al 1988, Persani et al 1998.…”

Section: Rthβmentioning

confidence: 99%

Triiodothyroacetic acid in health and disease

Groeneweg

Peeters

Visser

et al. 2017

Journal of Endocrinology

View full text Add to dashboard Cite

Thyroid hormone (TH) is crucial for development and metabolism of many tissues. The physiological relevance and therapeutic potential of TH analogs have gained attention in the field for many years. In particular, the relevance and use of 3,3′,5-triiodothyroacetic acid (Triac, TA 3 ) has been explored over the last decades. Although TA 3 closely resembles the bioactive hormone T 3 , differences in transmembrane transport and receptor isoformspecific transcriptional activation potency exist. For these reasons, the application of TA 3 as a treatment for resistance to TH (RTH) syndromes, especially MCT8 deficiency, is topic of ongoing research. This review is a summary of all currently available literature about the formation, metabolism, action and therapeutic applications of TA 3 .

show abstract

Section: Rthβmentioning

confidence: 99%

Triiodothyroacetic acid in health and disease

Groeneweg

Peeters

Visser

et al. 2017

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Clinically, 3,5,3 0 -triiodothyroacetic acid (TRIAC) was reported to be available for the management of thyrotoxicosis due to PRTH [18][19][20]. The molecular aspects revealed that TRIAC has a higher affinity for TRb1 than T3, whereas the two compounds show equivalent affinities for TRa1 [21,22].…”

Section: Therapeutic Approach and Optionsmentioning

confidence: 98%

Pituitary resistance to thyroid hormones: pathophysiology and therapeutic options

et al. 2011

View full text Add to dashboard Cite

Thyroid hormone secretion suppresses the expression of thyroid stimulating hormone (TSH), both of which are strictly controlled by a negative feedback loop between the hypothalamus-pituitary and thyroid. Pituitary resistance to thyroid hormone (PRTH) is defined as resistance to the action of thyroid hormone that is more severe in the pituitary than at the peripheral tissue level. Although the molecular basis of PRTH is not well understood, the clinical issue mainly involves imbalance between the hypothalamus-pituitary and peripheral thyroid hormone responsivity, which may induce peripheral thyrotoxic phenomena. Here, we review the pathogenesis and molecular aspects of PRTH, present a single case with inappropriate TSH secretion suffering from thyrotoxicosis treated with PTU, and discuss the possible choice of therapeutic options to correct the imbalance of thyroid hormone responsivity in both the hypothalamus-pituitary and peripheral tissues.

show abstract

“…The levothyroxine therapy should be conducted considering the clinical condition of these patients and imitating as much as possible the preoperative hormonal pattern for serum T 4 and T 3 even if optimal TSH suppression cannot be achieved (Paragliola et al 2011). Other drugs of interest which can suppress TSH secretion include triiodothyroacetic acid and dopamine agonists (Aguilar Diosdado et al 1991, Dulgeroff et al 1992.…”

Section: Treatmentmentioning

confidence: 99%

Thyrotoxicosis with concomitant thyroid cancer

Cheng

Jin

et al. 2019

Endocrine-Related Cancer

View full text Add to dashboard Cite

Thyrotoxicosis with concomitant thyroid cancer is rare and poorly recognized, which may result in delayed diagnosis, inappropriate treatment and even poor prognosis. To provide a comprehensive guidance for clinicians, the etiology, pathogenesis, diagnosis and treatment of this challenging setting were systematically reviewed. According to literatures available, the etiologies of thyrotoxicosis with concomitant thyroid cancer were categorized into Graves’ disease with concurrent differentiated thyroid cancer (DTC) or medullary thyroid cancer, Marine–Lenhart Syndrome with coexisting DTC, Plummer’s disease with concomitant DTC, amiodarone-induced thyrotoxicosis with concomitant DTC, central hyperthyroidism with coexisting DTC, hyperfunctioning metastases of DTC and others. The underlying causal mechanisms linking thyrotoxicosis and thyroid cancer were elucidated. Medical history, biochemical assessments, radioiodine uptake, anatomic and metabolic imaging and ultrasonography-guided fine-needle aspiration combined with pathological examinations were found to be critical for precise diagnosis. Surgery remains a mainstay in both tumor elimination and control of thyrotoxicosis, while anti-thyroid drugs, beta-blockers, 131I, glucocorticoids, plasmapheresis, somatostatin analogs, dopamine agonists, radiation therapy, chemotherapy and tyrosine kinase inhibitors should also be appropriately utilized as needed.

show abstract

Hyperthyroidism due to familial pituitary resistance to thyroid hormone: successful control with 3, 5, 3′ triiodothyroacetic associated to propranolol

Cited by 14 publications

References 23 publications

Triiodothyroacetic acid in health and disease

Triiodothyroacetic acid in health and disease

Pituitary resistance to thyroid hormones: pathophysiology and therapeutic options

Thyrotoxicosis with concomitant thyroid cancer

Contact Info

Product

Resources

About